A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment

Creative Commons License

Çelik B., Surucu Z. P., Yilmaz V., Celik H. K.

TURKISH THORACIC JOURNAL, cilt.19, sa.1, ss.49-51, 2018 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5152/turkthoracj.2018.030118
  • Dergi Adı: TURKISH THORACIC JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.49-51
  • Anahtar Kelimeler: Bilateral, pazopanib, pneumothorax, spontaneous, video-assisted thoracoscopic surgery
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Secondary spontaneous pneumothorax almost always develops secondary to an underlying lung disease. A pneumothorax secondary to a malignancy is very rare, and is observed most frequently in soft tissue sarcomas. Pazopanib, a tyrosine kinase inhibitor, is used in metastatic soft tissue sarcomas treatment. The rate of pneumothorax that is caused by pazopanib is about 14% in the literature. The patient being presented in this article underwent surgery for soft tissue sarcoma, postoperatively received pazopanib (Votrient (R) 400 mg, oral, Glaxo Group Ltd, Brentford, UK) treatment due to widespread bilateral lung metastases, and developed synchronous spontaneous pneumothorax.